Comparison of Doublet and Triplet Chemotherapy Regimens in Geriatric Patients with Metastatic Gastric Cancer

Authors : Yonca Yılmaz Ürün, Yaren Dirik, Nur Düzen Oflas, Gürkan Güner, Selcan Cesur, Muslih Ürün

Pages : 75-80

View : 66 | Download : 101

Publication Date : 2025-07-28

Article Type : Research Paper

Abstract :Introduction: There is a lack of guidelines for managing elderly metastatic gastric cancer patients. This study aimed to compare the efficacy and adverse events of doublet and triplet chemotherapy regimens in the first-line treatment of elderly patients with metastatic gastric cancer. Methods: We retrospectively evaluated geriatric metastatic gastric cancer patients who were treated at the Van Yüzüncü Yıl University Medical Faculty between 2011 and 2021. Demographic characteristics, treatment regimens and responses, grade 3-4 toxicity, progression-free survival (PFS), and overall survival (OS) were analyzed with appropriate statistical methods. Results: The mean age of the 224 patients was 73.8±3.6 years and 56 (25%) were female. Double-agent chemotherapy was administered to 99 (44.2%) patients, whereas 125 (55.8%) received triple-agent chemotherapy. The median OS was 9.8 months in the doublet group and 10.1 months in the triplet group (p=0.954). The median PFS was 5.8 months in the doublet group and 6.2 months in the triplet group, respectively (p=0.935). No statistically significant difference was found in terms of adverse events rates between groups. Conclusions: In this study, triplet chemotherapy had no additional toxicity, but also did not have a significant improvement in survival. Therefore, dual regimens, which may have lower toxicity in the geriatric population, may be considered preferable.
Keywords : Kemoterapi, mide kanseri, geriatri, birinci basamak tedavi

ORIGINAL ARTICLE URL